- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | A First-in-Class Treatment for Non-alcoholic Steatohepatitis | ||||||
| Small Molecules | NASH | HTR2A | Phase 1 | JD BIOSCIENCE INC. | RS-2023-00218035 | ||
| 2 | JP-2266: Novel SGLT1/2 dual inhibitor for the treatment of diabetes mellitus | ||||||
| Small Molecules | Diabetes | SGLT1/2 | Phase 1 | Jeil Pharmaceutical Co., Ltd. | HN21C0675 | ||